Diabetes insipidus

Diabetes insipidus is a rare disorder characterized by excessive urination and thirst due to impaired water balance in the body. It results from either deficient production of antidiuretic hormone or the kidney’s inability to respond to it. Early recognition is crucial to prevent dehydration and electrolyte imbalances.

Pathophysiology

Normal Water Homeostasis

Water balance in the body is primarily regulated by antidiuretic hormone (ADH), also known as vasopressin, which is produced by the hypothalamus and released from the posterior pituitary. ADH acts on the renal collecting ducts to increase water reabsorption, concentrating the urine and maintaining plasma osmolality within a narrow range. The thirst mechanism complements ADH action by regulating fluid intake.

Disruption in Diabetes Insipidus

Diabetes insipidus arises when this water homeostasis is disrupted. The main types include:

• Central (neurogenic) diabetes insipidus: Caused by a deficiency in ADH production or secretion from the hypothalamus or posterior pituitary.
• Nephrogenic diabetes insipidus: Results from renal resistance to ADH, where the kidneys fail to respond despite normal or elevated hormone levels.
• Gestational diabetes insipidus: A transient condition during pregnancy caused by increased degradation of ADH due to placental vasopressinase activity.

Etiology

Central Diabetes Insipidus

Causes of central diabetes insipidus include:

• Idiopathic, with no identifiable cause.
• Genetic mutations such as in the AVP gene or WFS1 gene affecting ADH synthesis or secretion.
• Acquired causes including head trauma, neurosurgery, tumors (pituitary adenomas, craniopharyngiomas), and infections affecting the hypothalamic-pituitary region.

Nephrogenic Diabetes Insipidus

Nephrogenic DI can result from:

• Genetic mutations causing congenital X-linked or autosomal forms.
• Acquired conditions including chronic kidney disease, medications such as lithium, hypercalcemia, and hypokalemia.

Gestational Diabetes Insipidus

Gestational diabetes insipidus occurs due to placental production of vasopressinase, an enzyme that degrades ADH. It is usually transient and resolves after delivery. Risk factors include multiple pregnancies and liver dysfunction which reduces enzyme clearance.

Clinical Features

Symptoms

Patients with diabetes insipidus typically present with the following symptoms:

• Polyuria: Excessive urine output often exceeding 3 liters per day in adults.
• Polydipsia: Intense thirst, particularly for cold water or beverages.
• Nocturia: Frequent urination during the night, disrupting sleep.
• Dehydration symptoms: Dry mouth, skin turgor loss, and fatigue.

Signs

On physical examination, notable signs may include:

• Hypernatremia due to free water loss.
• Hypotension or orthostatic changes in blood pressure.
• Signs of volume depletion such as tachycardia and decreased skin turgor.

Diagnostic Evaluation

Laboratory Tests

Laboratory investigations are essential for confirming the diagnosis and distinguishing the type of diabetes insipidus:

• Serum electrolytes, particularly sodium, to assess for hypernatremia.
• Plasma osmolality measurement to evaluate water balance.
• Urine osmolality and specific gravity, which are typically low in DI.
• Water deprivation test to differentiate central, nephrogenic, and primary polydipsia.

Imaging

Magnetic resonance imaging (MRI) of the hypothalamic-pituitary region may reveal structural abnormalities such as tumors, cysts, or post-surgical changes in central DI.

Differential Diagnosis

It is important to distinguish diabetes insipidus from other conditions causing polyuria and polydipsia:

• Primary polydipsia (psychogenic or dipsogenic).
• Hypercalcemia or hypokalemia.
• Uncontrolled diabetes mellitus causing osmotic diuresis.

Management

General Measures

Initial management focuses on maintaining adequate hydration and preventing electrolyte disturbances:

• Encouraging regular fluid intake to match urine output.
• Avoiding factors that may worsen water loss, such as diuretics or high-salt diets.
• Monitoring body weight and fluid balance to detect dehydration early.

Pharmacologic Therapy

Treatment depends on the type of diabetes insipidus:

• Central DI: Desmopressin (DDAVP), a synthetic analogue of ADH, administered orally, intranasally, or subcutaneously.
• Nephrogenic DI: Thiazide diuretics to reduce urine volume, nonsteroidal anti-inflammatory drugs to enhance renal concentrating ability, and correction of underlying electrolyte imbalances.
• Management of underlying causes such as discontinuation of offending drugs or treatment of structural lesions.

Monitoring

Regular monitoring is essential to ensure effective treatment and avoid complications:

• Serum sodium and osmolality to prevent hypernatremia or hyponatremia.
• Urine output and osmolality to assess response to therapy.
• Adjustment of medication dose based on clinical and laboratory parameters.

Complications

Untreated or poorly managed diabetes insipidus can lead to several complications, which may vary depending on severity and duration:

• Dehydration and hypernatremia: Resulting from excessive free water loss and inadequate fluid intake.
• Hypovolemic shock: Severe fluid depletion can lead to cardiovascular instability.
• Growth and developmental delays: Particularly in children if chronic dehydration occurs.
• Electrolyte imbalances: Including hypernatremia and secondary renal impairment due to persistent polyuria.

Prognosis

Central vs Nephrogenic Outcomes

The prognosis of diabetes insipidus varies depending on the type and underlying cause:

• Central DI: Generally favorable with appropriate desmopressin therapy, allowing patients to maintain normal hydration and electrolyte balance.
• Nephrogenic DI: May be more challenging to manage due to renal resistance, but careful fluid management, diet modification, and pharmacologic therapy can control symptoms effectively.

Impact of Early Diagnosis and Treatment

Early recognition and management significantly reduce the risk of complications such as severe dehydration, hypernatremia, and growth impairment in children. Prompt treatment allows patients to lead normal daily lives.

Long-term Management Considerations

Chronic diabetes insipidus requires ongoing monitoring of fluid status, electrolytes, and medication efficacy. Patient education on recognizing signs of dehydration and adjusting fluid intake is essential for long-term disease control.

References

1. Gleason CE, Kwong K, Kopple JD. Diabetes Insipidus. N Engl J Med. 2021;384(3):255-264.
2. Bourque CW. Central and nephrogenic diabetes insipidus. Endocrinol Metab Clin North Am. 2019;48(2):223-242.
3. Robertson GL. Diabetes Insipidus. Endocrine Reviews. 2020;41(3):503-541.
4. Baylis PH. Vasopressin and water balance disorders. Clin Endocrinol (Oxf). 2017;87(6):641-651.
5. Christ-Crain M, Bichet DG. Pathophysiology, diagnosis, and management of diabetes insipidus. Nat Rev Endocrinol. 2016;12(10):597-610.
6. Verbalis JG. Diabetes insipidus. Rev Endocr Metab Disord. 2018;19(2):107-121.
7. Schrier RW. Disorders of water metabolism. In: Jameson JL, De Groot LJ, editors. Endocrinology: Adult and Pediatric. 8th ed. Philadelphia: Elsevier; 2019. p. 330-346.